Skip to content

Study · Non-randomized trial · 2011

7 results

The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.

Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewki A, Vaal ML, Sriskandarajah L, Murphy KG, Farzad Z, Ghatei MA, Bloom SR, Dhillo WS

The Journal of clinical endocrinology and metabolism5 Oct 2011Cited by 105 (Europe PMC)

PMID21976724 (opens in a new tab)PMCIDPMC3232613 (opens in a new tab)DOI10.1210/jc.2011-1408 (opens in a new tab)PepBankPUB-21976724
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, intravenous bolus kisspeptin‑10 raised serum LH, at doses as low as 0.3 nmol/kg.

    In plain wordsIn healthy men, kisspeptin‑10 given into a vein raised blood LH, at doses as low as 0.3 nmol/kg.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseSerum LH after i.v. bolus kisspeptin-10 in healthy men
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    as low as 0.3 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    In healthy men, serum LH and FSH were elevated after i.v. bolus kisspeptin-10, at doses as low as 0.3 and 1.0 nmol/kg, respectively.
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy men, intravenous bolus kisspeptin‑10 raised serum FSH, at doses as low as 1.0 nmol/kg.

    In plain wordsIn healthy men, kisspeptin‑10 given into a vein raised blood FSH, at doses as low as 1.0 nmol/kg.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseSerum FSH after i.v. bolus kisspeptin-10 in healthy men
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    as low as 1.0 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    In healthy men, serum LH and FSH were elevated after i.v. bolus kisspeptin-10, at doses as low as 0.3 and 1.0 nmol/kg, respectively.
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy women in the follicular phase, intravenous bolus kisspeptin‑10 at a maximal dose of 10 nmol/kg did not change serum gonadotropins.

    In plain wordsIn healthy women early in the menstrual cycle, kisspeptin‑10 given into a vein did not change blood gonadotropin levels.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeSerum gonadotropins after i.v. bolus kisspeptin-10 in women, follicular phase
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    up to 10 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    In healthy women during the follicular phase of the menstrual cycle, no alterations in serum gonadotropins were observed after i.v. bolus, s.c. bolus, or i.v. infusion of kisspeptin-10 at maximal doses of 10 nmol/kg, 32 nmol/kg, and 720 pmol/kg/min, respectively.
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy women in the follicular phase, subcutaneous bolus kisspeptin‑10 at a maximal dose of 32 nmol/kg did not change serum gonadotropins.

    In plain wordsIn healthy women early in the menstrual cycle, kisspeptin‑10 injected under the skin did not change blood gonadotropin levels.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeSerum gonadotropins after s.c. bolus kisspeptin-10 in women, follicular phase
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    up to 32 nmol/kg · subcutaneous bolusAs given in this study (human).

    Source sentences

    Summary
    In healthy women during the follicular phase of the menstrual cycle, no alterations in serum gonadotropins were observed after i.v. bolus, s.c. bolus, or i.v. infusion of kisspeptin-10 at maximal doses of 10 nmol/kg, 32 nmol/kg, and 720 pmol/kg/min, respectively.
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy women in the follicular phase, intravenous infusion of kisspeptin‑10 at a maximal dose of 720 pmol/kg/min did not change serum gonadotropins.

    In plain wordsIn healthy women early in the menstrual cycle, a kisspeptin‑10 drip into a vein did not change blood gonadotropin levels.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeSerum gonadotropins during i.v. infusion of kisspeptin-10 in women, follicular phase
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    up to 720 pmol/kg/min · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    In healthy women during the follicular phase of the menstrual cycle, no alterations in serum gonadotropins were observed after i.v. bolus, s.c. bolus, or i.v. infusion of kisspeptin-10 at maximal doses of 10 nmol/kg, 32 nmol/kg, and 720 pmol/kg/min, respectively.
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women in the preovulatory phase, intravenous bolus kisspeptin‑10 (10 nmol/kg) raised serum LH.

    In plain wordsIn women just before ovulation, kisspeptin‑10 given into a vein raised blood LH.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseSerum LH after i.v. bolus kisspeptin-10 in women, preovulatory phase
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    In women during the preovulatory phase, serum LH and FSH were elevated after i.v. bolus kisspeptin-10 (10 nmol/kg).
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women in the preovulatory phase, intravenous bolus kisspeptin‑10 (10 nmol/kg) raised serum FSH.

    In plain wordsIn women just before ovulation, kisspeptin‑10 given into a vein raised blood FSH.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseSerum FSH after i.v. bolus kisspeptin-10 in women, preovulatory phase
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    In women during the preovulatory phase, serum LH and FSH were elevated after i.v. bolus kisspeptin-10 (10 nmol/kg).
    1 context sentence
    Summary · context
    Intravenous bolus kisspeptin-10 was administered to men and women (n = 4-5 per group). Subcutaneous bolus and i.v. infusion of kisspeptin-10 was also administered to female women (n = 4-5 per group). Circulating reproductive hormones were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03315325

Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

Quaid-e-Azam Universityn = 158 Aug 2014 to 5 Mar 2015

Sterility, Reproductive

Trial pageClinicalTrials.govUpdated 23 Oct 2017
CompletedPhase 3NCT03286517

Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

Ghulam Nabin = 3026 Jun 2014 to 5 Mar 2015

Reproductive Physiological Phenomena

Trial pageClinicalTrials.govUpdated 18 Sept 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.